Profit Before Tax (PBT): ₹30 crores, representing 27% YoY growth.
Profit After Tax (PAT): ₹25 crores, representing 37% YoY growth.
Earnings Per Share (EPS): ₹8.46.
Corporate Actions
The company completed a buyback of ₹47 crores, in which the promoters did not participate.
Declared a FY26 dividend of ₹13 crores, amounting to ₹6.30 per equity share.
Business Vertical Performance
Generic Formulations CDMO Vertical: Revenue of ₹207 crores, representing 29% YoY growth. Growth was driven by customer expansion, deeper engagement, and new product launches.
Trade Generics & Institutional Vertical: Revenue of ₹30 crores. Performance was impacted by the discontinuation of codeine-based products. The company is working on portfolio expansion and geographical expansion to bridge this gap.
Exports Vertical: Revenue of ₹11 crores, representing 79% YoY growth. The company remains focused on long-term growth through geography expansion, portfolio expansion, and plant approvals.
Operational and Strategic Updates
Plant 6: Mechanical completion is done. Validations and customer audits are ongoing. Commercialization is on track for H1 FY27 (expected around end of Q2 FY27). This expansion is expected to support a revenue potential of approximately ₹1,100 crores, with further upside possible through efficiency initiatives.
Capacity Utilization: Current utilization is around 65%. The company believes it can stretch utilization to 70% and further increase revenue potential through debottlenecking and operational capex (typically ₹12-15 crores annually).
Injectables Facility: The injectables dosage form is now contributing to revenue and is described as being "on track." Capacity expansion in this area, if needed, could be executed in 6-8 months as supportive infrastructure is already in place.
New Dosage Forms: There are no final updates on entering additional new dosage forms beyond injectables.
Industry Context and Outlook
The Indian Pharma Market (IPM) witnessed a volume growth of 3.4% in Q1 FY27.
Management emphasized a focus on long-term company-level performance over quarterly fluctuations in individual verticals.
Priorities include strengthening partnerships, expanding offerings, achieving operational excellence, and disciplined execution.
Q&A Session Highlights
CDMO Growth: Management cautioned against reading too much into the high 29% quarterly growth, attributing it to strong execution and the usual conversion of opportunities rather than a fundamental shift. The injectables facility contributed but was not the sole driver.
Trade Generics Recovery: The strategy to recover from the loss of codeine-based products involves expanding the product portfolio (SKUs), geographical expansion into new states, and improving sales force execution. No specific guidance was given on growth rates.
API Prices: Noted as volatile due to geopolitical factors and crude oil prices. The company operates on a cost-plus model, and customers are generally accommodating of price changes. The impact on Q1 revenue was described as unknown but likely minor compared to volume growth.
Margins: Gross margin performance was attributed to business mix, operational efficiencies, and a higher contribution from value-added products within the CDMO vertical, which helped offset the softer Trade Generics mix.
Working Capital: Some increase was noted during the quarter due to geopolitical factors leading to higher inventory and receivables, but levels were brought back to normal by the end of the period.
Depreciation: With the commissioning of Plant 6, quarterly depreciation is expected to increase by approximately ₹3 crores (₹30 million), with a full impact expected in Q3 FY27.
Personnel Costs: Increased 17% YoY due to annual increments, variable manpower linked to higher production, and a retrospective increase in minimum wages mandated by the Uttarakhand government.
Future Capex: The company's strategy is to add capacity incrementally rather than in large blocks. The next expansion would likely be a brownfield project for oral solids, which could be operational within about a year of a decision being made.
